公司概覽
業務類別 Biotechnology
業務概覽 Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
公司地址 12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
電話號碼 +1 858 558-2871
傳真號碼 +1 858 212-0513
公司網頁 https://www.acadia.com
員工數量 798
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Dr. Elizabeth H.Z. Thompson, PhD Executive Vice President and Head of Research and Development 美元 281.88K 25/04/2025
Mr. Thomas A. Garner Executive Vice President and Chief Commercial Officer -- 25/04/2025
Ms. Catherine Owen Adams Director and Chief Executive Officer 美元 245.77K 26/02/2026
Mr. James K. Kihara Senior Vice President, Finance, Controller and Chief Accounting Officer -- 26/02/2026
Mr. Mark C. Schneyer Executive Vice President and Chief Financial Officer 美元 518.47K 26/02/2026
Ms. Jennifer J. Rhodes Executive Vice President, Chief Legal Officer and Secretary 美元 478.03K 25/04/2025
 
董事會成員
董事會 職務 更新日期
Mr. Julian C. Baker Independent Director 26/02/2026
Ms. Laura A. Brege Independent Director 26/02/2026
Mr. James M. Daly Independent Director 26/02/2026
Dr. Stephen R. Biggar,M.D.,PhD Chairman of the Board 26/02/2026
Mr. Jonathan Poole Director 05/03/2026
Dr. Edmund P. Harrigan, M.D. Independent Director 26/02/2026
Ms. Catherine Owen Adams Director and Chief Executive Officer 26/02/2026
Dr. Elizabeth A. Garofalo, M.D. Independent Director 26/02/2026
Dr. Adora Ndu, Pharm.D. Independent Director 26/02/2026
 
所屬ETF (更新日期: 07/03/2026 04:17)
代號 名稱 佔比% 持有日期
SPITF/m Emerald Special Situations ETF0.01%27/02/2026
DCORDimensional US Core Equity 1 ETF0.01%27/02/2026
OASCOneAscent Enhanced Small and Mid Cap ETF0.01%27/02/2026
AGNGGlobal X Aging Population ETF0.01%27/02/2026
ROSCHartford Multifactor Small Cap ETF0.01%28/02/2026
SMMViShares MSCI USA Sm-Cp Min Vol Fctr ETF0.01%28/02/2026
SYZLazard US Systematic Small Cap Eq ETF0.01%28/02/2026
FLQSFranklin US Small Cap Mltfctr Idx ETF0.01%28/02/2026
XJRiShares ESG Select Scrn S&P Small-CapETF0.01%28/02/2026
SMLVState Street® SPDR® USSmCapLowVolIndETF0.01%27/02/2026
VTHRVanguard Russell 3000 ETF0.01%31/01/2026
IBBQInvesco Nasdaq Biotechnology ETF0.01%27/02/2026
OMFSInvesco Russell 2000® Dynamic Mltfct ETF0.01%27/02/2026
WSMLiShares MSCI World Small-Cap ETF0.01%28/02/2026
BIBProShares Ultra Nasdaq Biotechnology0.005%27/02/2026
UWMProShares Ultra Russell20000.005%27/02/2026
URTYProShares UltraPro Russell20000.005%27/02/2026
IBRNiShares Neuroscience and Healthcare ETF0.004%28/02/2026
BKSEBNY Mellon US Small Cap Core Equity ETF0.003%28/02/2026
ISCBiShares Morningstar Small-Cap ETF0.003%28/02/2026
  1    2    3   4    5    6    7  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.